Moneycontrol PRO
Upcoming Webinar:Innovate Your Future at India Inc. on the Move on August 26 and 27, 2021 at 10am, with Rockwell Automation
you are here: HomeNewsIndia

COVID-19 vaccine | Serum's Covishield, Bharat Biotech's Covaxin 'not considered' for emergency use authorisation: Sources

Both Bharat Biotech and Serum Institute of India have been asked by the Subject Expert Committee to furnish more data, trial information, and documents

December 09, 2020 / 06:26 PM IST

The Central Drugs Standard Control Organisation (CDSCO) has sought more data from Serum Institute of India (SII) and Bharat Biotech in order to clear their COVID-19 vaccine candidates for emergency use in the country, sources said on December 9.

Applications seeking emergency use authorisation for Oxford-AstraZeneca's Covishield, being manufactured by SII, and Covaxin, being developed by Bharat Biotech, were not considered for clearance by the Subject Expert Committee (SEC) due to "lack of safety" and inadequate data on efficacy, the sources told News18.

"Both proposals were not considered due to inadequate safety and efficiency data available currently. Both the companies have been asked for more data," the sources said.

"Both Bharat Biotech and SII will need to come back again to the SEC with more data, trial information, and documents," the sources added.

Bharat Biotech declined to comment, while SII hasn't responded to messages from Moneycontrol seeking comment on the drug regulator's decision.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The CDSCO expert panel took the decision in its meeting held on December 9 to review the applications of Pfizer, SII, and Bharat Biotech.

"It is standard practice for the government to hold several meetings. The process is expected to go on for one or two weeks," NDTV quoted sources in SII as saying.

Pune-based SII and Hyderabad-based Bharat Biotech had applied for emergency use authorisation (EUA) of their respective vaccine candidates on December 6 and 7, respectively.

The Indian arm of the US pharmaceutical giant Pfizer on December 4 sought approval for its vaccine from the drug regulator after the firm secured clearance in the UK and Bahrain.

The UK became the first country in the world to began immunizing its citizens against the viral disease when it rolled out Pfizer's vaccine on December 8.
Moneycontrol News
first published: Dec 9, 2020 05:51 pm
Sections
ISO 27001 - BSI Assurance Mark